SEARCH

SEARCH BY CITATION

References

  • 1
    Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998; 17: 4854.
  • 2
    Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004; 3: 33952.
  • 3
    Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 212532.
  • 4
    Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 12839.
  • 5
    Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 3527.
  • 6
    Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004; 63: 100914.
  • 7
    MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001; 40: 4539.
  • 8
    Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 98993.
  • 9
    Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 51622.
  • 10
    Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 34450.
  • 11
    Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 13444.
  • 12
    Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007; 26: 1817.
  • 13
    D'Alonzo GE, Barst RJ, Ayres SM, Bergotsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 3439.
  • 14
    Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003; 29: 33549, vii.
  • 15
    Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 92632.
  • 16
    Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al. Treatment of patients with mildly symptomatic pulmonary hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093100.
  • 17
    Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 142536.
  • 18
    Rich S. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest 1998; 114(3 Suppl): 237S41S.
  • 19
    Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37: 48594.
  • 20
    Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 108893.
  • 21
    Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792800.
  • 22
    Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 12738.
  • 23
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 58190.
  • 24
    Miller MR, Crapo R, Hankinson J, Van Der Grinten CP, Gustafsson P, Jensen R et al. General considerations for lung function testing. Eur Respir J 2005; 26: 15361.
  • 25
    Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 91923.
  • 26
    Lang R, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards committee and Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 144063.
  • 27
    Hatle L, Angelsen BA, Tromsdal A. Non-invasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. Br Heart J 1981; 45: 15765.
  • 28
    Rich S. Primary Pulmonary Hypertension: Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France; Geneva: The World Health Organization; 1998.
  • 29
    Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Med J Aust 2003; 178: 5647.
  • 30
    Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 2004; 25: 224378.
  • 31
    Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298304.
  • 32
    Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35: 2833.
  • 33
    Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 6574.
  • 34
    Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110: 151519.
  • 35
    Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124: 2098104.
  • 36
    Celermajer DS, Marwick T. Echocardiographic and right heart catheterization techniques in patients with pulmonary arterial hypertension. Int J Cardiol 2008; 125: 294303.
  • 37
    McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl): 14S34S.
  • 38
    Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43: 4616.
  • 39
    Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007; 116: 63747.
  • 40
    Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003; 92: 14348.
  • 41
    Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 178894.
  • 42
    Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 21623.
  • 43
    Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 153344.
  • 44
    Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 133640.
  • 45
    Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 26974.
  • 46
    Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30: 2398405.
  • 47
    Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156(2 Pt 1): 52835.